| Name | Title | Contact Details |
|---|
Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company`s expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of six clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors.
Norbrook® is a true innovator and dedicated to novel research and revolutionary processes and products. Lord Ballyedmond, Founder, Chairman and CEO of the Norbrook Group began his career in the pharmaceutical industry in the USA in the 1960s and now controls the largest privately owned pharmaceutical company in the world. The company is very active in both medical and veterinary products. Research and Development is the key to Norbrook`s success with the R&D Department central to the company`s structure. It is responsible for new product development, technical support and meeting regulatory and licensing protocols. Norbrook invests more than 10% of its turnover annually in research and development of new products. The company is at the forefront of formulation technology and has developed many new chemical routes for the synthesis of active materials. Norbrook has formulated and registered more than 800 products in 120 countries. The on-going success of the company is conditional on the expertise, knowledge and innovation of the staff employed. Norbrook prides itself on attracting the highest calibre of individual to the company and boasts a multi-national workforce committed to constantly pushing the boundaries and challenging technologies to ensure that Norbrook remains the leading force in pharmaceuticals that it is today.
Clinical ink is the global life science company that brings data, technology, and patient-centric research together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.
Cellular Engineering Technologies, Inc. is a Coralville, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.